Geneoscopy Wins PTAB Decision Invalidating Exact Sciences’ Patent No. 11,970,746
ByAinvest
Friday, Feb 6, 2026 4:07 pm ET1min read
EXAS--
Geneoscopy has won a second Patent Trial and Appeal Board decision, invalidating all challenged claims of Exact Sciences' '746 patent. This follows the PTAB's July 2025 decision invalidating all claims of Exact Sciences' '781 patent. The PTAB ruled that the challenged claims are unpatentable due to prior art describing stool sample collection and processing. This clears the path for Geneoscopy to continue commercializing ColoSense, a colorectal cancer screening solution.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet